☆ 4.3 Editorial Material

Obinutuzumab (GA101) - a different anti-CD20 antibody with great expectations

EXPERT OPINION ON BIOLOGICAL THERAPY (2012)

Get Full Text
Add to Collection

Journal

EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 12, Issue 5, Pages 543-545

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1517/14712598.2012.668881

Keywords

CD20; immunotherapy; lymphoid malignancies; mAb; newer agents

Categories

Biotechnology & Applied Microbiology Medicine, Research & Experimental

Funding

  1. Cancer Research UK [11335] Funding Source: Medline
  2. Cancer Research UK [11335] Funding Source: researchfish

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.